1.1 | Report Scope |
1.1.1 | Report Coverage |
1.1.2 | Assumptions And Limitations |
1.1.3 | Market Classification & Segmentation |
1.2 | Research Methodology |
1.2.1 | Data Points Considered For Market Size Estimation |
1.2.2 | Key Data Point Sources |
1.2.2.1 | Key Data Points From Primary Sources |
1.2.2.2 | Key Data Points From Secondary Sources |
1.2.3 | Data Triangulation |
1.2.4 | Top-Down Approach |
1.2.5 | Bottom-Up Approach |
1.3 | Report Description |
A quick peek into the report
Table of Contents
Report Overview
Executive Summary
2.1 | Global Market Scenario |
Market Overview
3.1 | Introduction |
3.2 | Pharmacogenomics: Mechanism Of Action |
3.3 | Role Of Companion Diagnostics In PGX |
3.4 | Role Of Biomarkers In PGX |
3.5 | Role Of Molecular Diagnostics In PGX |
3.6 | Benefits Of PGX |
3.7 | End-Use Applications Of PGX |
3.8 | Market Dynamics |
3.8.1 | Market Drivers |
3.8.2 | Market Challenges |
3.8.3 | Market Opportunities |
Competitive Insights
4.1 | Key Market Developments & Strategies |
4.1.1 | Competitive Landscape Of Some Of The Key Players |
4.1.2 | Partnerships, Joint Ventures And Collaborations |
4.1.2.1 | Key Insights |
4.1.2.2 | Recent Partnerships, Joint Ventures And Collaborations |
4.1.3 | Product Launch And Developments |
4.1.3.1 | Key Insights |
4.1.3.2 | Recent Product Launch And Developments |
4.1.4 | Patents, Licensing, Certification And Approvals |
4.1.4.1 | Key Insights |
4.1.4.2 | Recent Patents, Licensing, Certification And Approvals |
4.1.5 | Mergers And Acquisitions |
4.1.5.1 | Key Insights |
4.1.5.2 | Recent Mergers And Acquisitions |
4.1.6 | Business Contracts And Business Expansions |
4.1.6.1 | Key Insights |
4.1.6.2 | Recent Business Contracts And Business Expansions |
4.1.7 | Other Strategies |
4.1.7.1 | Key Insights |
4.1.7.2 | Recent Developments Of Other Strategies |
4.2 | Porter’s Five Forces Analysis |
4.2.1 | Threat Of Substitutes |
4.2.2 | Threat Of New Entrants |
4.2.3 | Bargaining Power Of Buyers |
4.2.4 | Bargaining Power Of Suppliers |
4.2.5 | Intensity Of Competitive Rivalry |
Industry Analysis
5.1 | Patent Analysis |
5.1.1 | Some Of The Key Players |
5.1.2 | Others (University/Hospital/Person) |
5.2 | Regulations, Consortiums, Certifications, & Standards |
5.2.1 | Regulatory Bodies |
5.2.2 | Examples Of Some Common Acts Certifications |
5.3 | Value Chain Analysis |
Global Pharmacogenomics Market By Technology
6.1 | Market Segmentation By Technology |
6.2 | Microarray |
6.2.1 | Introduction |
6.2.2 | Microarray: Types, Applications & Key Players |
6.2.3 | Microarray: Market Dynamics & Recent Developments |
6.3 | Sequencing |
6.3.1 | Introduction |
6.3.2 | Sequencing: Market Dynamics, Applications & Key Players |
6.3.3 | Types Of Sequencing Technologies |
6.3.3.1 | Sanger Sequencing |
6.3.3.2 | Pyrosequencing |
6.3.3.3 | Next-Gen Sequencing (NGS) |
6.3.3.3.1 | Next-Gen Sequencing (NGS) Applications & Key Players |
6.3.3.3.2 | Next-Gen Sequencing (NGS) Recent Developments |
6.4 | Polymerase Chain Reaction (PCR) |
6.4.1 | Introduction |
6.4.2 | PCR Types |
6.4.3 | PCR: Market Dynamics, Applications & Key Players |
6.5 | Other Technologies |
6.5.1 | Mass Spectrometry |
6.5.2 | Electrophoresis |
Global Pharmacogenomics Market By Ecosystem Players
7.1 | PGX Ecosystem Players: Overview |
7.2 | Market Segmentation By Ecosystem Players |
7.2.1 | Market Insights & Statistics |
7.3 | Diagnostic Test Companies |
7.3.1 | Introduction |
7.3.2 | Market Statistics |
7.3.3 | Diagnostic Companies: Drivers & Challenges |
7.3.4 | Recent Key Developments |
7.3.5 | Key Players |
7.4 | Pharmaceuticals Companies |
7.4.1 | Introduction |
7.4.2 | Market Statistics |
7.4.3 | Drug Development Process |
7.4.4 | Role Of Pharmaceutical Companies & Example Of Some Drugs |
7.4.5 | Pharmaceuticals Companies: Drivers & Challenges |
7.4.6 | Recent Key Developments |
7.4.7 | Key Players |
7.5 | Service Providers |
7.5.1 | Introduction |
7.5.2 | Market Statistics |
7.5.3 | Service Provider: Roles & Big Data Benefits |
7.5.4 | Big Data Companies: Drivers & Challenges |
7.5.5 | Recent Key Developments |
7.5.6 | Key Players |
Global Pharmacogenomics Market By Therapeutic Applications
8.1 | Market Segmentation |
8.2 | Market Statistics |
8.3 | Cancer/Oncology |
8.3.1 | Key Insights & Statistics |
8.3.2 | Market Statistics |
8.3.3 | Types Of Cancer |
8.3.4 | Cancer: Examples Of Some Drugs |
8.3.5 | Cancer: Examples Of Some Tests |
8.3.6 | Market Dynamics & Key Players |
8.3.7 | Recent Key Developments |
8.4 | Cardiovascular Diseases (CVD) |
8.4.1 | Key Insights & Statistics |
8.4.2 | Market Statistics |
8.4.3 | CVD: Examples Of Some Drugs |
8.4.4 | CVD: Examples Of Some Tests |
8.4.5 | Recent Key Developments & Key Players |
8.5 | Central Nervous System(CNS) |
8.5.1 | Key Insights & Statistics |
8.5.2 | Market Statistics |
8.5.3 | CNS: Examples Of Some Drugs |
8.5.4 | CNS: Examples Of Some Tests |
8.5.5 | Recent Key Developments & Key Players |
8.6 | Infectious Diseases |
8.6.1 | Key Insights & Statistics |
8.6.2 | Market Statistics |
8.6.3 | Infectious Diseases : Examples Of Some Drugs |
8.6.4 | Recent Key Developments & Key Players |
8.7 | Other Diseases |
8.7.1 | Key Insights & Statistics |
8.7.2 | Market Statistics |
8.7.3 | Other Diseases : Examples Of Some Drugs |
8.7.4 | Other Diseases : Examples Of Some Tests |
8.7.5 | Recent Key Developments & Key Players |
Global Pharmacogenomics Market By Geography
9.1 | Geographical Scenario |
9.2 | Market Insights & Statistics |
9.3 | North America |
9.3.1 | Market Scope |
9.3.2 | North America: Market Insights & Statistics |
9.3.3 | North American Market Dynamics |
9.3.4 | Key Regulatory Bodies & Associations |
9.3.5 | The U.S. |
9.3.5.1 | The U.S.: Market Statistics |
9.3.5.2 | The U.S.: Key Insights |
9.3.6 | Canada |
9.3.7 | Recent Key Developments |
9.4 | Europe |
9.4.1 | Market Scope |
9.4.2 | Europe: Market Insights & Statistics |
9.4.3 | European Market Dynamics |
9.4.4 | Key Regulatory Bodies & Associations |
9.4.5 | The U.K. |
9.4.6 | Germany |
9.4.7 | Recent Key Developments |
9.5 | Asia-Pacific (APAC) |
9.5.1 | Market Scope |
9.5.2 | APAC: Market Insights & Statistics |
9.5.3 | APAC Market Dynamics |
9.5.4 | China |
9.5.5 | Japan |
9.5.6 | India |
9.5.7 | Recent Key Developments |
9.6 | Rest Of The World (ROW) |
9.6.1 | ROW: Market Insights & Statistics |
9.6.2 | Middle East |
9.6.3 | South America |
9.6.4 | Africa |
9.6.5 | Recent Key Development |
Company Overview
10.1 | Abbott Laboratories |
10.1.1 | Overview |
10.1.2 | Financials |
10.1.3 | Financial Summary |
10.1.4 | Key Developments |
10.1.5 | SWOT Analysis |
10.2 | Affymetrix, Inc. |
10.2.1 | Overview |
10.2.2 | Financials |
10.2.3 | Financial Summary |
10.2.4 | Key Developments |
10.2.5 | SWOT Analysis |
10.3 | Assurex Health, Inc. |
10.3.1 | Overview |
10.3.2 | Key Developments |
10.3.3 | SWOT Analysis |
10.4 | Astrazeneca |
10.4.1 | Overview |
10.4.2 | Financials |
10.4.3 | Financial Summary |
10.4.4 | Key Developments |
10.4.5 | SWOT Analysis |
10.5 | Illumina, Inc. |
10.5.1 | Overview |
10.5.2 | Financials |
10.5.3 | Financial Summary |
10.5.4 | Key Developments |
10.5.5 | SWOT Analysis |
10.6 | Laboratory Corporation Of America Holdings |
10.6.1 | Overview |
10.6.2 | Financials & Financial Summary |
10.6.3 | Key Developments |
10.6.4 | SWOT Analysis |
10.7 | Myriad Genetics, Inc. |
10.7.1 | Overview |
10.7.2 | Financials & Financial Summary |
10.7.3 | Key Developments |
10.7.4 | SWOT Analysis |
10.8 | Pfizer, Inc. |
10.8.1 | Overview |
10.8.2 | Financials |
10.8.3 | Financial Summary |
10.8.4 | Key Developments |
10.8.5 | SWOT Analysis |
10.9 | Qiagen, Inc. |
10.9.1 | Overview |
10.9.2 | Financials |
10.9.3 | Financial Summary |
10.9.4 | Key Developments |
10.9.5 | SWOT Analysis |
10.10 | Roche Holding AG-BR |
10.10.1 | Overview |
10.10.2 | Financials |
10.10.3 | Financial Summary |
10.10.4 | Key Developments |
10.10.5 | SWOT Analysis |
10.11 | TEVA Pharmaceutical Industries Ltd. |
10.11.1 | Overview |
10.11.2 | Financials |
10.11.3 | Financial Summary |
10.11.4 | Key Developments |
10.11.5 | SWOT Analysis |
10.12 | Thermo Fisher Scientific |
10.12.1 | Overview |
10.12.2 | Financials |
10.12.3 | Financial Summary |
10.12.4 | Key Developments |
10.12.5 | SWOT Analysis |
10.13 | Transgenomic, Inc. |
10.13.1 | Overview |
10.13.2 | Financials & Financial Summary |
10.13.3 | Key Developments |
10.13.4 | SWOT Analysis |
10.14 | Other Emerging Companies |
10.14.1 | Diagnostic Test Companies |
10.14.1.1 | Companiondx Reference Lab, LLC |
10.14.1.2 | Mapmy Genome |
10.14.1.3 | Asuragen |
10.14.1.4 | 23andme |
10.14.1.5 | Cnsdose |
10.14.2 | Pharmaceutical Companies |
10.14.2.1 | Actinium Pharmaceuticals, Inc |
10.14.2.2 | Foundation Medicine |
10.14.3 | Service Providers |
10.14.3.1 | PGX Software LLC |
10.14.3.2 | Gene Logic |
10.14.3.3 | Genewiz |
10.14.3.4 | Conatus Consulting, LLC |
10.14.4 | Care Providers |
10.14.4.1 | Gene DX |
10.14.4.2 | Mayo Clinic |
List Of Acronyms
11.1 | List Of Acronyms |
List Of Figures
1 | Year Consideration |
2 | Market Classification & Segmentation |
3 | Research Methodology |
4 | Global Pharmacogenomics Market ($Billion) |
5 | Global Pharmacogenomics Market Value, 2015-2022 ($Billion) |
6 | Global PGX Market, By Ecosystem, 2015-2022 ($Billion) |
7 | Global PGX Market Share, By Therapeutic Application, 2015-2022 ($Billion) |
8 | Global Pharmacogenomics Market, By Geography-2022 |
9 | Mechanism Of Action |
10 | Role Of Companion Diagnostics In PGX |
11 | Role Of Biomakers In PGX |
12 | Role Of Molecular Diagnostics IN PGX |
13 | Benefits Of PGX |
14 | End-Use Applications Of PGX |
15 | Market Dynamics |
16 | Partnerships, Joint Ventures And Collaborations: Key Players Analysis |
17 | Product Launch And Developments: Key Players Analysis |
18 | Patents, Licensing, Certification And Approvals : Key Players Analysis |
19 | Mergers And Acquisitions: Key Players Analysis |
20 | Business Contracts And Business Expansions : Key Players Analysis |
21 | Others Strategies: Key Players Analysis |
22 | Porter’s Five Forces Analysis |
23 | Threat Of Substitutes |
24 | Threat Of New Entrants |
25 | Bargaining Power Of Buyers |
26 | Bargaining Power Of Suppliers |
27 | Intensity Of Competitive Rivalry |
28 | Roles And Responsibilities Of Healthcare Policy Makers |
29 | Role Of FDA In PGX |
30 | Classification Of Medical Devices |
31 | Examples Of Some Common Acts |
32 | Example Of Some Certifications |
33 | Value Chain Analysis |
34 | Example Of Some Significant Players In PGX Value Chain |
35 | Generalized Process For The Microarray |
36 | Different Types Of Microarrays |
37 | Applications Of Microarrays |
38 | Microarray- Drivers & Challenges |
39 | Sequencing Technologies In PGX |
40 | Sequencing - Drivers & Challenges |
41 | Applications Of Sequencing |
42 | NGS- Drivers & Challenges |
43 | Applications Of NGS |
44 | Generalized Process For PCR |
45 | Different Types Of PCR |
46 | PCR - Drivers & Challenges |
47 | Applications Of PCR |
48 | Applications Of Mass Spectrometry |
49 | Applications Of Electrophoresis |
50 | Overview Of PGX Ecosystem Players |
51 | Global PGX Market By Ecosystem Players |
52 | Global Pharmacogenomics Market, By Ecosystem , 2015-2022 ($Billion) |
53 | Global PGX Ecosystem Market, By Diagnostic Tests Companies, 2015-2022 ($Billion) |
54 | Global PGX Diagnostic Tests Market, By Therapeutic Applications, 2015-2022 ($Billion) |
55 | Global PGX Diagnostic Tests Market, By Geography, 2015-2022 ($Billion) |
56 | Diagnostic Companies- Drivers & Challenges |
57 | Global PGX Ecosystem Market, By Pharmaceutical Companies, 2015-2022 ($Billion) |
58 | Global PGX Pharmaceutical Market, By Therapeutic Applications, 2015-2022 ($Billion) |
59 | Global PGX Pharmaceutical Market, By Geography, 2015-2022 ($Billion) |
60 | Drug Development Process |
61 | Role Of Pharmaceuticals Companies |
62 | Pharmaceuticals Companies- Drivers & Challenges |
63 | Global PGX Ecosystem Market, By Service Providers, 2015-2022 ($Billion) |
64 | Global PGX Service Providers Market, By Therapeutic Applications, 2015-2022 ($Billion) |
65 | Global PGX Service Providers Market, By Geography, 2015-2022 ($Billion) |
66 | Three Data Drivers Of PGX Market |
67 | Benefits Of Big Data |
68 | Big Data Companies- Drivers & Challenges |
69 | Global PGX Market By Therapeutics Applications |
70 | Global PGX Market, By Theraeutics Application, 2015-2022 ($Billion) |
71 | Global PGX Market By Oncology,2015-2022($Billion) |
72 | Global PGX Oncology Market, By Ecosystem, 2015-2022 ($Billion) |
73 | Global PGX Oncology Market, By Geography, 2015-2022 ($Billion) |
74 | Types Of Cancer |
75 | Oncology Market Dynamics |
76 | Global PGX Market By CVD, 2015-2022 ($Billion) |
77 | Global PGX CVD Market, By Ecosystem, 2015-2022 ($Billion) |
78 | Global PGX CVD Market, By Geography, 2015-2022 ($Billion) |
79 | Global PGX Market By CNS, 2015-2022 ($Billion) |
80 | Global PGX CNS Market, By Ecosystem, 2015-2022 ($Billion) |
81 | Global PGX CNS Market, By Geography, 2015-2022 ($Billion) |
82 | Global PGX Market By Infectious Diseases, 2015-2022 ($Billion) |
83 | Global PGX Infectious Diseases Market, By Ecosystem, 2015-2022 ($Billion) |
84 | Global PGX Infectious Diseases Market, By Geography, 2015-2022 ($Billion) |
85 | Global PGX Market By Other Diseases, 2015-2022 ($Billion) |
86 | Global PGX Other Diseases Market, By Ecosystem, 2015-2022 ($Billion) |
87 | Global PGX Other Diseases Market, By Geography, 2015-2022 ($Billion) |
88 | Growth Trajectory Of PGX Market |
89 | Global Pharmacogenomics Market, By Geography , 2015-2022 ($Billion) |
90 | Global Pharmacogenomics Market, By Geography (2015) |
91 | North American PGX Market, 2015 |
92 | North American PGX Market, 2015-2022 ($Billion) |
93 | North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) |
94 | North American Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion) |
95 | North American Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) |
96 | North American Market Dynamics |
97 | Key Regulatory Bodies & Associations |
98 | The U.S. PGX Market, 2015-2022 ($Billion) |
99 | The U.S. Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion) |
100 | The U.S. Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) |
101 | Canada PGX Market Dynamics |
102 | European PGX Market, 2015 |
103 | European PGX Market,2015-2022($Billion) |
104 | European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) |
105 | European Pharmacogenomics Market, By Ecosystem, 2015-2022 ($Billion) |
106 | European Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) |
107 | European Market Dynamics |
108 | Key Regulatory Bodies & Associations |
109 | The U.K. PGX Market, 2015-2022 ($Billion) |
110 | The Germany PGX Market, 2015-2022 ($Billion) |
111 | APAC Country-Wise CAGR Of PGX Market |
112 | APAC PGX Market, 2015-2022 ($Billion) |
113 | APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) |
114 | APAC Pharmacogenomics MARKET,BY Ecosystem, 2015-2022 ($Billion) |
115 | APAC Pharmacogenomics Market, By Therapeutic Applications, 2015-2022 ($Billion) |
116 | APAC Market Dynamics |
117 | The China PGX Market, 2015-2022 ($Billion) |
118 | China Market Dynamics |
119 | The Japan PGX Market, 2015-2022 ($Billion) |
120 | The Indian PGX Market, 2015-2022 ($Billion) |
121 | Indian Market Dynamics |
122 | Region-Wise CAGR Of PGX Market |
123 | ROW PGX Market, 2015-2022 ($Billion) |
124 | ROW PGX Market, By Sub-Region, 2015-2022 ($Billion) |
125 | ROW PGX Market, By Ecosystem, 2015-2022 ($Billion) |
126 | ROW PGX Market, By Therapeutics, 2015-2022 ($Billion) |
127 | Middle East PGX Market, 2015-2022 ($Billion) |
128 | South American PGX Market, 2015-2022 ($Billion) |
129 | African PGX Market, 2015-2022 ($Billion) |
130 | : Abbott Laboratories, Inc.– Overall Financials, 2013-2015 ($Billion) |
131 | Abbott Laboratories, Inc.- Financials By Business Segments, 2013-2015 ($Billion) |
132 | Abbott Laboratories, Inc.– Financials By Geography, 2013-2015 ($Billion) |
133 | Abbott Laboratories, Inc.- SWOT Analysis |
134 | Affymetrix, Inc.– Overall Financials, 2013-2015 ($Million) |
135 | Affymetrix, Inc.- Financials By Business Segments, 2013-2015 ($Million) |
136 | Affymetrix, Inc.– Financials By Geography,2013-2015 ($Million) |
137 | Affymetrix, Inc.- SWOT Analysis |
138 | Assurex Health, Inc.- SWOT Analysis |
139 | Astrazeneca – Overall Financials, 2013-2015 ($Billion) |
140 | Astrazeneca- Financials By Business Segments, 2013-2015 ($Billion) |
141 | Astrazeneca– Financials By Geography,2013-2015 ($Billion) |
142 | Astrazeneca- SWOT Analysis |
143 | Illumina, Inc.– Overall Financials, 2013-2015 ($Million) |
144 | Illumina, Inc.- Financials By Business Segments, 2013-2015 ($Million) |
145 | Illumina, Inc.– Financials By Geography, 2013-2015 ($Million) |
146 | Illumina, Inc.- SWOT Analysis |
147 | Laboratory Corporation Of America Holding.- Overall Financials, 2013-2015 ($Million) |
148 | Laboratory Corporation Of America Holding—Financials By Business Segments, 2013-2015 ($ Million) |
149 | Laboratory Corporation Of America Holding.- SWOT analysis |
150 | Myriad Genetics, Inc.– Overall Financials, 2013-2015 ($Million) |
151 | Myriad Genetics, Inc.– Financials By Business Segments, 2013-2015 ($Million) |
152 | Myriad Genetics,INC.- SWOT Analysis |
153 | Pfizer, Inc.– Overall Financials, 2013-2015 ($Billion) |
154 | Pfizer,Inc. – Financials By Geography ,2013-2015 ($Billion) |
155 | Pfizer, Inc.- Financials By Business Segments, 2014-2015 ($Billion) |
156 | Pfizer, Inc.– Financials By Business Segment, 2013 |
157 | Pfizer, Inc.- SWOT analysis |
158 | Qiagen– Overall Financials, 2013-2015 ($Million) |
159 | Qiagen- Financials By Business Segments, 2013-2015 ($Million) |
160 | Qiagen– Financials By Geography, 2013-2015 ($Million) |
161 | Qiagen- SWOT Analysis |
162 | Roche Holding– Overall Financials,2013-2015 ($Billion) |
163 | Roche Holding- Financials By Business Segments, 2013-2015 ($Billion) |
164 | Roche Holding– Financials Of Diagnostics Division By Geography, 2013-2015 ($Billion) |
165 | Roche Holding– Financials Of Pharmaceuticals,SEGMENT By Geography, 2013-2015 ($Billion) |
166 | Roche Holding- SWOT Analysis |
167 | TEVA Pharmaceutical Ltd.– Overall Financials, 2013-2015 ($Billion) |
168 | TEVA Pharmaceutical Ltd.- Financials By Business Segments, 2013-2015 ($Billion) |
169 | TEVA Pharmaceutical Ltd.– Financials By Geography, 2013-2015 ($Billion) |
170 | TEVA Pharmaceutical Industries Ltd.- SWOT analysis |
171 | Thermo Fisher, Inc.- Overall Financials, 2013-2015 ($Billion) |
172 | Thermo Fisher, Inc.— Financials By Business Segments, 2013-2015 ($Billion) |
173 | Thermo Fisher, Inc.— Financials By Geography, 2013-2015 ($Billion) |
174 | Thermo Fisher Scientific, Inc.- SWOT Analysis |
175 | Transgenomic, Inc.- Overall Financials,2013-2015 ($Million) |
176 | Transgenomic, Inc.- Financials By Business SEGEMENTS, 2013-2015 ($Million) |
177 | Transgenomic, Inc.- SWOT Analysis |
List of Tables
1 | Competitive Landscape: Some Of The Key Players |
2 | Recent Partnerships, Joint Ventures And Collaborations |
3 | Recent Product Launch And Developments |
4 | Recent Patents, Licensing, Certification And Approvals |
5 | Recent Mergers And Acquisitions |
6 | Recent Business Contracts And Business Expansions |
7 | Recent Developments Of Other Strategies |
8 | Patent Analysis Of Some Key Players |
9 | Patent Analysis Of Some University/Hospital/Person |
10 | Microarray- Recent Key Developments |
11 | NGS- Recent Key Developments |
12 | Difference Between Realt Time & Digital PCR |
13 | Diagnostic Test Companies- Recent Key Developments |
14 | Example Of Some Pharmacogenomic Drugs |
15 | Pharmaceuticals Companies- Recent Key Developments |
16 | Service Providers- Recent Key Developments |
17 | Cancer- Examples Of Some Drugs |
18 | Cancer- Examples Of Some Tests |
19 | Oncology- Recent Key Developments |
20 | CVD- Examples Of Some Drugs |
21 | CVD- Examples Of Some Tests |
22 | CNS- Examples Of Some Drugs |
23 | CNS- Examples Of Some Tests |
24 | Infectious Diseases- Examples Of Some Drugs |
25 | Other Diseases- Examples Of Some Drugs |
26 | North American Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) |
27 | North American Pharmacogenomics Market Recent Key Dvelopments |
28 | European Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) |
29 | European PGX Market Recent Key Developments |
30 | APAC Pharmacogenomics Market, By Country Wise, 2015-2022 ($Billion) |
31 | APAC Pharmacogenomics Market Recent Key Developments |
32 | ROW Pharmacogenomics Market,By Sub-Region, 2015-2022 |
33 | ROW Recent Key Development |
34 | Abbott Laboratories, Inc. Recent Developments |
35 | Affymetrix, Inc. Recent Developments |
36 | Assurex Health, Inc. Recent Developments |
37 | Astrazeneca Recent Developments |
38 | Illumina, Inc. Recent Developments |
39 | Laboratory Corporation Of America Holding Recent Developments |
40 | Myriad Genetics Recent Developments |
41 | Pfizer, Inc. Recent Developments |
42 | Qiagen Recent Developments |
43 | Roche Holding Recent Developments |
44 | TEVA Pharmaceutical Industries Ltd. Recent Developments |
45 | Thermo Fisher, Inc. Recent Developments |
46 | Transgenomic, Inc. Recent Developments |
Global Pharmacogenomics (PGx) Market Analysis
Focus On Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography– Estimation & Forecast 2022